- $2.98bn
- $3.16bn
- $441.54m
- 78
- 13
- 69
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 51.93 | ||
| PEG Ratio (f) | 1.59 | ||
| EPS Growth (f) | 48.55% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.06 | ||
| Price to Tang. Book | 13.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.76 | ||
| EV to EBITDA | 55.11 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.04% | ||
| Return on Equity | 19.39% | ||
| Operating Margin | 8.49% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 25.64 | 30.26 | 93.46 | 241.62 | 441.54 | 542.53 | 653.91 | 79.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +839.91 | +45.48 | +53.52 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Directors
- James Tobin NEC (76)
- Waleed Hassanein PRE (52)
- Stephen Gordon CFO (53)
- John Carey VOP (56)
- Laura Damme VPR (57)
- Miriam Provost VPR (60)
- John Sullivan VPR (56)
- Tamer Khayal OTH (52)
- Edward Basile IND (73)
- Thomas Gunderson IND (70)
- Edwin Kania IND (63)
- Stephanie Lovell IND (60)
- Merilee Raines IND (65)
- David Weill IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 11th, 2018
- Public Since
- May 2nd, 2019
- No. of Shareholders
- 20
- No. of Employees
- 728
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 33,827,880
- Address
- 200 Minuteman Road, ANDOVER, 01810
- Web
- https://www.transmedics.com/
- Phone
- +1 9785520900
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for TMDX
Transmedics Group Inc Annual Shareholders Meeting
Transmedics Group Inc Annual Shareholders Meeting
Q2 2025 Transmedics Group Inc Earnings Release
Similar to TMDX
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the TransMedics share price?
As of Today at 23:46 UTC, shares in TransMedics are trading at $88.24. This share price information is delayed by 15 minutes.
How has the TransMedics share price performed this year?
Shares in TransMedics last closed at $88.24 and the price had moved by +0.43% over the past 365 days. In terms of relative price strength the TransMedics share price has underperformed the S&P500 Index by -5.57% over the past year.
What are the analyst and broker recommendations for TransMedics?
The overall consensus recommendation for TransMedics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the TransMedics dividend yield?
TransMedics does not currently pay a dividend.
Does TransMedics pay a dividend?
TransMedics does not currently pay a dividend.
When does TransMedics next pay dividends?
TransMedics does not currently pay a dividend.
How do I buy TransMedics shares?
To buy shares in TransMedics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TransMedics?
As of the previous close price of $88.24, shares in TransMedics had a market capitalisation of $2.98bn.
Where are TransMedics shares listed?
Here are the trading details for TransMedics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TMDX
What kind of share is TransMedics?
Based on an overall assessment of its quality, value and momentum TransMedics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TransMedics share price forecast for 2025?
The analyst consensus target price for shares in TransMedics is $115.63. That is 31.04% above the last closing price of $88.24.
Analysts covering TransMedics currently have a consensus Earnings Per Share (EPS) forecast of $1.47 for the next financial year.
Find out moreWhat is the trend in the TransMedics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TransMedics. Over the past six months, its share price has underperformed the S&P500 Index by -22.76%.
As of the last closing price of $88.24, shares in TransMedics were trading -15.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TransMedics PE Ratio?
The TransMedics PE ratio based on its reported earnings over the past 12 months is 51.93. The shares last closed at $88.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TransMedics?
TransMedics' management team is headed by:
- James Tobin - NEC
- Waleed Hassanein - PRE
- Stephen Gordon - CFO
- John Carey - VOP
- Laura Damme - VPR
- Miriam Provost - VPR
- John Sullivan - VPR
- Tamer Khayal - OTH
- Edward Basile - IND
- Thomas Gunderson - IND
- Edwin Kania - IND
- Stephanie Lovell - IND
- Merilee Raines - IND
- David Weill - IND